| human | Q5 |
| P8446 | Gateway to Research person ID | 30E889E0-0982-43A8-BC4D-056E33DDF36F |
| P496 | ORCID iD | 0000-0002-0397-245X |
| P1153 | Scopus author ID | 35274135700 |
| P69 | educated at | University of Birmingham | Q223429 |
| P108 | employer | University of Dundee | Q1249005 |
| Astex Therapeutics | Q4810825 | ||
| P734 | family name | Wyatt | Q21500882 |
| Wyatt | Q21500882 | ||
| Wyatt | Q21500882 | ||
| P735 | given name | Paul | Q4925623 |
| Paul | Q4925623 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q46775768 | 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics |
| Q52664543 | 2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure-Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization. |
| Q58745060 | A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors |
| Q30044020 | A novel multiple-stage antimalarial agent that inhibits protein synthesis |
| Q58866392 | Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need |
| Q39003990 | Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need |
| Q104741284 | Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action Studies |
| Q41781992 | Antitumor quinol PMX464 is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolism |
| Q58850070 | Author Correction: Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need |
| Q36753140 | Chemical proteomic analysis reveals the drugability of the kinome of Trypanosoma brucei. |
| Q24657204 | Chemical validation of trypanothione synthetase: a potential drug target for human trypanosomiasis |
| Q38966911 | Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay |
| Q51711730 | Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis. |
| Q56565594 | Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis |
| Q27677088 | De Novo Design of Protein Kinase Inhibitors by in Silico Identification of Hinge Region-Binding Fragments |
| Q47102566 | Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors. |
| Q34097455 | Design, synthesis and biological evaluation of Trypanosoma brucei trypanothione synthetase inhibitors |
| Q34619406 | Design, synthesis and biological evaluation of novel inhibitors of Trypanosoma brucei pteridine reductase 1. |
| Q33193553 | Detection of ligands from a dynamic combinatorial library by X-ray crystallography. |
| Q42543989 | Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides |
| Q27671819 | Dihydroquinazolines as a Novel Class of Trypanosoma brucei Trypanothione Reductase Inhibitors: Discovery, Synthesis, and Characterization of their Binding Mode by Protein Crystallography |
| Q38919697 | Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi |
| Q35791902 | Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei |
| Q35779255 | Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library |
| Q27676019 | Discovery of a Novel Class of Orally Active Trypanocidal N -Myristoyltransferase Inhibitors |
| Q37412029 | Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy |
| Q28749049 | Drug Discovery in Academia- the third way? |
| Q57932465 | Editorial [Hot Topic: Progress in Neglected Disease Drug Discovery (Guest Editors: Andrew L. Hopkins & Paul G. Wyatt)] |
| Q58842879 | Erratum for De Rycker et al., Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay |
| Q27644255 | Essential but not vulnerable: indazole sulfonamides targeting inosine monophosphate dehydrogenase as potential leads against Mycobacterium tuberculosis |
| Q28534499 | Exploring the Trypanosoma brucei Hsp83 potential as a target for structure guided drug design |
| Q27653420 | Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity |
| Q34887882 | Fragment-based hit identification: thinking in 3D. |
| Q34775438 | From on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules |
| Q97548524 | Identification and optimisation of a series of 8-hydroxy naphthyridines with potent in vitro antileishmanial activity: Initial SAR and assessment of in vivo activity |
| Q90661828 | Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis |
| Q89257069 | Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB |
| Q27644553 | Identification of inhibitors of protein kinase B using fragment-based lead discovery |
| Q38948559 | Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3. |
| Q28216655 | Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives |
| Q43981490 | Identification of potent and selective oxytocin antagonists. Part 2: further investigation of benzofuran derivatives |
| Q30897674 | Investigation of trypanothione reductase as a drug target in Trypanosoma brucei |
| Q34725554 | Lead optimization of a pyrazole sulfonamide series of Trypanosoma brucei N-myristoyltransferase inhibitors: identification and evaluation of CNS penetrant compounds as potential treatments for stage 2 human African trypanosomiasis |
| Q33309109 | Lessons learnt from assembling screening libraries for drug discovery for neglected diseases |
| Q62997191 | Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis |
| Q24594745 | N-myristoyltransferase inhibitors as new leads to treat sleeping sickness |
| Q27655956 | One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening |
| Q33990598 | Optimisation of the anti-Trypanosoma brucei activity of the opioid agonist U50488 |
| Q90090011 | PE/PPE proteins mediate nutrient transport across the outer membrane of Mycobacterium tuberculosis |
| Q58867156 | Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani |
| Q64068249 | Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition |
| Q35761636 | Quinol derivatives as potential trypanocidal agents |
| Q47162276 | Screening a protein kinase inhibitor library against Plasmodium falciparum |
| Q49330155 | Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA. |
| Q91750784 | Setting Our Sights on Infectious Diseases |
| Q43552108 | Sialidase inhibitors related to zanamivir. Further SAR studies of 4-amino-4H-pyran-2-carboxylic acid-6-propylamides |
| Q104753737 | Structure-Activity Relationships of Pyrazolo[1,5-a]pyrimidin-7(4H)-ones as Antitubercular Agents |
| Q37658475 | Structure-activity relationship studies of pyrrolone antimalarial agents |
| Q34088830 | Synthesis and evaluation of 1-(1-(Benzo[b]thiophen-2-yl)cyclohexyl)piperidine (BTCP) analogues as inhibitors of trypanothione reductase |
| Q34301994 | Target assessment for antiparasitic drug discovery |
| Q35237566 | Target validation: linking target and chemical properties to desired product profile |
Search more.